Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
Neuland Laboratories announced that its first commercial peptide manufacturing module is now operational. The company's second module is planned to have a total reactor capacity of up to 18,000 litres, including specific reactor sizes for different manufacturing processes. This development marks a step in the company's manufacturing capabilities.
Neuland Laboratories' management participated in several investor and analyst meetings in September 2026. These included a group meeting with Emkay Global Investors on September 15, 2026, and an ICICI Securities Healthcare Day group meet on September 17, 2026. Additionally, the company was scheduled to participate in the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 23-25, 2026, which included a one-on-one meeting with Goldman Sachs analyst Shyam Srinivasan on September 23, 2026.
As of September 18, 2026, Neuland Laboratories has shown varied returns across different timeframes. The stock has returned 44% over the past year and 52% year-to-date. More recently, it has seen a 33% return in the last three months and an 84% return in the last six months. However, the return over the last month was -2%.
As of September 18, 2026, Neuland Laboratories' stock is trading near several technical levels. Key resistance levels identified are at ₹22,921.67 (0.36% higher), ₹23,178.33 (1.48% higher), ₹23,376.67 (2.35% higher), and ₹23,500.00 (2.89% higher). Support levels are noted at ₹22,723.33 (0.51% lower), ₹22,526.00 (1.37% lower), ₹22,466.67 (1.63% lower), and ₹22,268.33 (2.50% lower).
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹641.58 crore | PEAK₹776.25 crore | ₹439.71 crore | ₹514.27 crore | ₹292.75 crore |
| Expenses | ₹452.22 crore | PEAK₹501.21 crore | ₹393.29 crore | ₹386.64 crore | ₹283.04 crore |
| Profit Before Tax | ₹197.85 crore | PEAK₹287.49 crore | ₹54.48 crore | ₹129.44 crore | ₹17.57 crore |
| Profit Loss For Period | ₹147.67 crore | PEAK₹212.67 crore | ₹40.57 crore | ₹96.85 crore | ₹13.90 crore |
| Tax Expense | ₹50.17 crore | PEAK₹74.82 crore | ₹13.90 crore | ₹32.58 crore | ₹3.67 crore |
| Basic Earnings Loss Per Share From Continuing And Discontinued Operations | ₹115.10 per share | PEAK₹165.76 per share | ₹31.62 per share | ₹75.49 per share | ₹10.83 per share |
Neuland Laboratories reported revenue of ₹641.58 crore and net profit of ₹147.67 crore for the first quarter of FY2026-27. Both figures more than doubled compared to the same quarter last year, though they declined sequentially from the prior quarter's results. Profit margins widened significantly on a year-over-year basis but contracted slightly compared to the previous quarter.
Revenue from operations reached ₹641.58 crore in the current quarter, up 119% from ₹292.75 crore a year ago. This represents a ₹348.82 crore absolute increase. On a sequential basis, revenue fell 17% from ₹776.25 crore in the fourth quarter of FY2025-26. The current quarter's revenue ranks as the second highest among the five available quarters, trailing only the prior quarter.
Basic and diluted earnings per share were both ₹115.10. This compares to ₹10.83 a year ago, representing a 963% increase, and ₹165.76 in the prior quarter, reflecting a 31% sequential decline.
Neuland Laboratories delivered substantial year-over-year growth in revenue and profit for the first quarter of FY2026-27, with both metrics more than doubling from the same period last year. The sequential decline from the prior quarter reflects a step-down from a higher baseline. Profitability margins remain well above year-ago levels despite a slight sequential contraction, driven by revenue growth outpacing expense growth over the twelve-month period.
Exchange disclosures and regulatory announcements for Neuland Laboratories.
Neuland Laboratories Limited announced that its management will participate in the Goldman Sachs Global Healthcare CDMO Day, a group and one-on-one meeting scheduled for September 23-25, 2026, in Singapore. The company disclosed this schedule via an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, dated September 16, 2026. The filing notes that the meeting schedule and participant list remain subject to change due to exigencies.
Neuland Laboratories Limited announced an in-person institutional investor meeting scheduled for September 23, 2026, at 07:30 AM in Singapore. The event is the Goldman Sachs Global Healthcare CDMO Day, where the company will meet with Goldman Sachs analyst Shyam Srinivasan to discuss its business operations.
Neuland Laboratories Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Press Release". |SUBJECT: Press Release
Neuland Laboratories Limited announced on September 9, 2026, that its management will participate in two institutional investor meetings scheduled for September 15 and September 17, 2026. The first event is a group meeting with Emkay Global Investors, followed by the ICICI Securities Healthcare Day group meet. The company noted that the schedule and participant lists are subject to change due to exigencies.
Neuland Laboratories will participate in an institutional investor meeting on September 17, 2026, at 16:15, hosted by ICICI Securities at the Hyderabad Healthcare Day in Hyderabad. The meeting is a group, in-person session with analyst Abdulkader Puranwala to discuss the company.
On September 7, 2026, the Board of Directors of Neuland Laboratories Limited approved a capital expenditure of ₹126 crores to purchase approximately 134 acres of land in Auro Industrial City, Kakinada, Andhra Pradesh, for future expansion. The company retains a right of first refusal to acquire an additional 66 acres later, potentially increasing the total holding to 200 acres. This investment is scheduled to be financed through internal accruals.
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
Recent market and company developments associated with Neuland Laboratories.
Neuland Labs' second module is planned to have a total reactor capacity of up to 18,000 litres. It will include three 5,000-litre LPPS reactors, either a 1,000-litre or 2,000-litre SPPS reactor, and smaller reactors of up to 1,000 litres.
Vijay Kedias investment approach is built as much around discipline as opportunity. He is willing to buy stocks after sharp declines but refuses to chase them when valuations move beyond his comfort zone. As mutual funds, family offices and other investors crowd into emerging businesses, Kedia is increasingly looking at SMEs, unlisted companies and startups for opportunities that offer attractive valuations and growth potential.
Shares of Inox Wind, Kaynes Technology, LIC Housing Finance and SAIL barred from fresh F&O positions on 7 September 2026.
Neuland Laboratories will invest Rs 126 crore to acquire 134 acres in Kakinada, with an option for 66 more acres, to support future expansion.
Shares of Neuland Laboratories Ltd ended at ₹22,955.00, up by ₹311.70, or 1.38%, on the BSE.
Investor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the companys promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with solid fundamentals, which has ultimately fostered substantial wealth growth over the years.
Retail, FMCG, insurance and pharma dominated another busy day of results, but the biggest market moves came from the details hidden beneath the headline numbers.
Sensex, Nifty, Share Prices LIVE: Sensex was up 160.95 pts or 0.20% to 78,741.95 at 9.16 am after opening at 78,782.43 from the previous close of 78,581; Nifty inched up 8.70 pts or 0.04% to 24,633.35.
Comprehensive Section Breakdown for Neuland Laboratories
Strategic Vision: Global CDMO specializing in Active Pharmaceutical Ingredients (APIs).
• Expertise in overcoming chemistry challenges in drug development.
• Legacy as a pure-play API manufacturer since 1984.
Profit before tax stood at ₹197.85 crore, a 1,026% increase from ₹17.57 crore a year ago and a 31% decrease from ₹287.49 crore in the prior quarter. After accounting for a tax expense of ₹50.17 crore, which implies an effective tax rate of 25.4%, net profit came in at ₹147.67 crore. This marks a 962% year-over-year rise from ₹13.90 crore and a 31% sequential drop from ₹212.67 crore.
The net profit margin expanded to 23.0% in the current quarter, compared to 4.7% a year ago. However, this represents a contraction from the 27.4% margin recorded in the prior quarter. The year-over-year margin expansion occurred because revenue grew at a faster pace than total expenses over the twelve-month period.
Total expenses were ₹452.22 crore, up 60% from ₹283.04 crore a year ago and down 10% from ₹501.21 crore in the fourth quarter. The sequential decline in expenses was smaller in percentage terms than the sequential decline in revenue, which contributed to the slight compression in profit margins compared to the prior quarter.
Profit before tax of ₹197.85 crore exceeded the difference between revenue and total expenses (₹189.36 crore) by ₹8.49 crore. This difference aligns with the reported other income of ₹8.49 crore for the quarter, which added directly to pre-tax earnings.
Management reported Q1FY27 was broadly in line with expectations, with both CMS and GDS businesses showing encouraging performance. While commercial products drove most revenue, the company highlighted exciting developments in its pipeline projects and noted that customer conversations are now significantly deeper, focusing on broader capability-led discussions rather than individual projects. Management emphasized that the intensity of investments will further increase based on the opportunities available, and all significant Capex projects are proceeding as planned. Working capital days improved to 84 from 137 in Q4FY26, and net debt turned negative at Rs -308.5 crore, reflecting a strong cash position.
Neuland announced a strategic partnership with Gland Pharma to establish a sterile API manufacturing suite for microparticle depot products, combining Neuland's complex API expertise with Gland's sterile manufacturing capabilities. The suite will add approximately 1,400 kg of annual capacity to serve growing global demand for sterile APIs. Separately, the Board approved a capacity expansion of 18 KL at Unit 1 (current utilization 91%) with an investment of Rs 39.8 crore, financed through internal accruals, to meet increasing customer demand. The CMS pipeline remains robust with 99 active projects, including 19 at commercial stage, and traction is building with innovators for peptide molecules.
Category: Manufacturing
Neuland Laboratories develops and manufactures non-exclusive APIs, including large-volume 'Prime APIs' and lower-volume, complex 'Specialty APIs'.
Key Products & Services: Prime APIs • Specialty APIs
Category: B2B Services
These services cover the entire lifecycle of drug development, from initial stages to commercial production, including process development, optimization, analytical testing, and regulatory support.
Category: Manufacturing
Neuland Laboratories provides development and manufacturing services for peptides, ranging from milligram to multi-kilogram scales using chemical synthesis strategies.
Core Thesis: The company supports biotechnology and pharmaceutical companies by providing expertise in the design, development, and manufacturing of complex APIs.
• End-to-End Service Continuum: The company supports drug development from early-stage (Pre-IND) through to commercial manufacturing, encompassing process development, optimization, analytical testing, and regulatory support. • Project-Oriented Approach: Neuland Laboratories operates with a project-oriented approach, fostering collaborative customer relationships that emphasize agility, transparency, and quality. • Sustainability and ESG Integration: The company actively integrates sustainability and Environmental, Social, and Governance (ESG) priorities into its operations across six key themes.